A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen

Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestati...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Yuki, Hitaka, Daisuke, Kido, Takahiro, Kanai, Yu, Konishi, Kumi, Doki, Kosuke, Katayama, Nobuko, Homma, Masato, Miyazono, Yayoi, Takada, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399775/
https://www.ncbi.nlm.nih.gov/pubmed/32774971
http://dx.doi.org/10.1155/2020/2056756
_version_ 1783566209653932032
author Okada, Yuki
Hitaka, Daisuke
Kido, Takahiro
Kanai, Yu
Konishi, Kumi
Doki, Kosuke
Katayama, Nobuko
Homma, Masato
Miyazono, Yayoi
Takada, Hidetoshi
author_facet Okada, Yuki
Hitaka, Daisuke
Kido, Takahiro
Kanai, Yu
Konishi, Kumi
Doki, Kosuke
Katayama, Nobuko
Homma, Masato
Miyazono, Yayoi
Takada, Hidetoshi
author_sort Okada, Yuki
collection PubMed
description Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies. This case presents detailed information on the development of an infant with placental transfer of tamoxifen. The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues.
format Online
Article
Text
id pubmed-7399775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73997752020-08-07 A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen Okada, Yuki Hitaka, Daisuke Kido, Takahiro Kanai, Yu Konishi, Kumi Doki, Kosuke Katayama, Nobuko Homma, Masato Miyazono, Yayoi Takada, Hidetoshi Case Rep Pediatr Case Report Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies. This case presents detailed information on the development of an infant with placental transfer of tamoxifen. The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues. Hindawi 2020-07-26 /pmc/articles/PMC7399775/ /pubmed/32774971 http://dx.doi.org/10.1155/2020/2056756 Text en Copyright © 2020 Yuki Okada et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Okada, Yuki
Hitaka, Daisuke
Kido, Takahiro
Kanai, Yu
Konishi, Kumi
Doki, Kosuke
Katayama, Nobuko
Homma, Masato
Miyazono, Yayoi
Takada, Hidetoshi
A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title_full A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title_fullStr A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title_full_unstemmed A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title_short A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
title_sort follow-up report of an infant born to a mother receiving tamoxifen
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399775/
https://www.ncbi.nlm.nih.gov/pubmed/32774971
http://dx.doi.org/10.1155/2020/2056756
work_keys_str_mv AT okadayuki afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT hitakadaisuke afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT kidotakahiro afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT kanaiyu afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT konishikumi afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT dokikosuke afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT katayamanobuko afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT hommamasato afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT miyazonoyayoi afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT takadahidetoshi afollowupreportofaninfantborntoamotherreceivingtamoxifen
AT okadayuki followupreportofaninfantborntoamotherreceivingtamoxifen
AT hitakadaisuke followupreportofaninfantborntoamotherreceivingtamoxifen
AT kidotakahiro followupreportofaninfantborntoamotherreceivingtamoxifen
AT kanaiyu followupreportofaninfantborntoamotherreceivingtamoxifen
AT konishikumi followupreportofaninfantborntoamotherreceivingtamoxifen
AT dokikosuke followupreportofaninfantborntoamotherreceivingtamoxifen
AT katayamanobuko followupreportofaninfantborntoamotherreceivingtamoxifen
AT hommamasato followupreportofaninfantborntoamotherreceivingtamoxifen
AT miyazonoyayoi followupreportofaninfantborntoamotherreceivingtamoxifen
AT takadahidetoshi followupreportofaninfantborntoamotherreceivingtamoxifen

Ejemplares similares